AI drug developer Insilico Medicine and Lilly ink commercialization deal worth up to $2.75 billion - statnews.com
AI drug developer Insilico Medicine and Lilly ink commercialization deal worth up to $2.75 billion - statnews.com 📰 Published by AI News Automation 🔗 Read Full Original Article AI Drug Developer Insilico Medicine and Lilly Ink Commercialization Deal Worth Up to $2.75 Billion AI Drug Developer Insilico Medicine and Lilly Ink Multi-Billion Dollar Commercialization Deal In a landmark development set to reshape the future of pharmaceutical innovation, AI drug discovery pioneer Insilico Medicine has announced a significant commercialization deal with global pharmaceutical leader Eli Lilly and Company. This monumental partnership could be worth up to an astounding $2.75 billion, underscoring the rapidly growing impact and validation of artificial intelligence in accelerating the drug development pipeline. A L...